Business Wire

MN-DIGI-INTERNATIONAL

Share
Digi International Launches Digi Containers to Improve Development, Operation, and Management of Custom Applications on Digi Cellular Routers

Digi International, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched Digi Containers, a software service that enables the development and operation of custom applications on Digi cellular routers that run DAL OS. Digi Containers leverage the Digi Remote Manager® platform as the central portal for deploying and managing these applications.

The Digi Containers service helps developers take the fullest advantage of edge computing by providing the flexibility to deploy new services and apps while consolidating edge-processing hubs. These edge applications offer low latency and near-real-time responsiveness with the agility to respond to evolving use cases.

Through Digi Containers, developers employ Lightweight Linux Containers (LXCs) — essentially virtual machines (VMs) that share the physical device’s running kernel. This enables processes inside a container to run at native speed as if they are actually running directly on the host device. Since containers are lightweight and portable, they offer both security and flexibility. This enables developers to expand on the capabilities of Digi solutions to support specific needs.

As a value-added service for Digi cellular routers, Digi Containers enable users to upload, manage, deploy, and monitor container-based applications through Digi Remote Manager. This empowers companies to orchestrate and manage a complex series of containers in various structures and configurations. Digi Containers provide:

  • Portability – A containerized application can be deployed in private and public clouds. Companies gain flexibility because they can easily move workloads among environments and providers.
  • Scalability – Containers can scale horizontally (i.e., you can “clone” identical containers within the same cluster to expand capacity/throughput as needed). By running only what is needed, when needed, costs decrease significantly.
  • Increased security – By design, containers are inherently isolated. If one container is compromised, others won’t be affected.
  • Speed – Autonomy from the operating system gives greater control. You can start/stop a container in seconds. You achieve faster development and operational speed and a faster and smoother user experience.
  • Efficiency – Since a separate operating system isn’t required, containers require fewer resources than VMs. You can run several containers on a single server. Less hardware means lower costs and fewer points of failure.

“The launch of Digi Containers unlocks the power of edge computing on Digi cellular routers,” said Kinana Hussain, Vice President of Product Management. “By building in the embedded software environment on our devices, along with their inherent computational capabilities, developers can tap into a rich and growing set of features, capabilities, and services. These are all signed, vetted, and distributed as part of the Digi TrustFence® security framework to more easily create and support a variety of demanding containerized applications in the enterprise, industrial, and transportation markets.”

Digi Enhances Network Analytics Application

Recently, Digi also upgraded Digi intelliFlow® in Digi Remote Manager, further strengthening Digi’s edge-to-cloud software stack. Digi intelliFlow provides a graphical visualization of network application data, focusing on the top 10 users or top 10 destinations. This intuitive representation of network activity allows organizations to update settings on Digi routers or tailor the network to the site’s needs. Digi intelliFlow provides recent data and a historical reference to keep networks running smoothly. intelliFlow addresses excessive data usage with custom alarms that alert administrators when data limits are approaching.

“Our long-term vision is to enable a full suite of market vertical-specific value-added services that leverage our robust edge-to-cloud software stack to help our customers maximize their IoT investments while focusing on their core business,” said Hussain.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005154/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release

The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow

DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release

MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa

VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release

Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye